Compare JBSS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | DSGN |
|---|---|---|
| Founded | 1959 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 905.7M | 819.6M |
| IPO Year | 1994 | 2021 |
| Metric | JBSS | DSGN |
|---|---|---|
| Price | $83.84 | $13.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $109.00 | $15.25 |
| AVG Volume (30 Days) | 114.2K | ★ 794.1K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $1,107,246,000.00 | N/A |
| Revenue This Year | $5.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.95 | ★ N/A |
| Revenue Growth | ★ 3.79 | N/A |
| 52 Week Low | $59.07 | $3.33 |
| 52 Week High | $85.15 | $17.25 |
| Indicator | JBSS | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 71.17 | 67.46 |
| Support Level | $73.95 | $9.78 |
| Resistance Level | $84.75 | $17.10 |
| Average True Range (ATR) | 1.80 | 0.73 |
| MACD | 0.75 | 0.45 |
| Stochastic Oscillator | 94.37 | 82.96 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.